All In Biotech

Drug Trial Radar · NCT02301091

Combine TACE and RFA Versus TACE Alone for HCC With PVTT

Combine Transcatheter Arterial Embolization and Radiofrequency Ablation Versus Transcatheter Arterial Embolization Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Last checked: Nov 20, 2026Latest source record: Apr 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

240

Planned (sponsor's estimate)

Start

Oct 2014

Primary completion

Oct 2018

Study completion Oct 2019

Sponsor

Lead sponsor
Ming ZhaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether combined radiofrequency ablation and transcatheter chemoembolization (TACE) result in better survival outcomes than TACE alone in patients with HCC and portal vein tumor thrombus.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • TACEProcedure

    TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.

  • RFAProcedure

    For RFA, we used two commercially available system (Cool-Tip, Valleylab,USA) and (Octopus RF Systema,Starmed,Korea)with needle electrode with a 17-gauge internally cooled electrode.

  • pirarubicin,mitomycin and lobaplatinDrug

    They were cytotoxic drugs used in the TACE procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival ratesTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.